Adial Pharmaceuticals (ADIL) Share-based Compensation (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Share-based Compensation of $86200.0 for Q1 2026, down 85.03% sequentially from $575700.0 in Q4 2025, and down 63.59% YoY from $236731.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Share-based Compensation (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Share-based Compensation for 10 years, with the latest figure at $86200.0 in Q1 2026.
- Quarterly Share-based Compensation fell 63.59% year-over-year to $86200.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $906194.0 (down 23.45% YoY) and the FY2025 annual result came in at $676200.0, down 1.78% from the prior year.
- Share-based Compensation retreated to $86200.0 in Q1 2026 per ADIL's latest filing, from $575700.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $688463.0 in Q4 2024 and troughed at -$2.2 million in Q4 2022.
- A 5-year average of $213415.8 and a median of $293665.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 89.05% in 2023, then jumped 184.87% in 2024.
- Over 5 years, Share-based Compensation stood at -$2.2 million in 2022, then surged by 112.63% to $280847.0 in 2023, then surged by 145.14% to $688463.0 in 2024, then slipped by 16.38% to $575700.0 in 2025, then sank by 85.03% to $86200.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $86200.0, $575700.0, and $508164.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Adial Pharmaceuticals | 27.13 Mn | 27.13 Mn | - | 137,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86,200.00 |
| Mar 31, 2026 | 86,200.00 |
| Dec 31, 2025 | 575,700.00 |
| Dec 31, 2025 | 575,700.00 |
| Sep 30, 2025 | 508,164.00 |
| Sep 30, 2025 | 508,164.00 |
| Jun 30, 2025 | 75,099.00 |
| Jun 30, 2025 | 75,099.00 |
| Mar 31, 2025 | 236,731.00 |
| Mar 31, 2025 | 236,731.00 |
| Dec 31, 2024 | 688,463.00 |
| Dec 31, 2024 | 688,463.00 |
| Sep 30, 2024 | 616,629.00 |
| Sep 30, 2024 | 616,629.00 |
| Jun 30, 2024 | 153,391.00 |
| Jun 30, 2024 | 153,391.00 |
| Mar 31, 2024 | 177,003.00 |
| Mar 31, 2024 | 177,003.00 |
| Dec 31, 2023 | 280,847.00 |
| Dec 31, 2023 | 280,847.00 |